GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 13, 2025.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Midcap 150 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, along with an unmodified audit opinion from Deloitte Haskins & Sells LLP. Standalone revenue from operations rose to Rs. 3,723 crore (FY24: Rs. 3,407 crore), about 9% growth, while profit after tax jumped to Rs. 919 crore (FY24: Rs. 585 crore), a 57% increase aided by the absence of last year's one-time VRS charge. Profit before exceptional items and tax grew about 31% to Rs. 1,244 crore, reflecting strong margin expansion. Operating cash flow remained robust at Rs. 1,280 crore standalone. The board recommended a final dividend of Rs. 42 per share (vs Rs. 32 last year), with record date May 30, 2025 and payment from June 30, 2025. Dr. Sunita Maheshwari was re-appointed as Independent Director for a second 3-year term, and Parikh & Associates was appointed as Secretarial Auditor for FY2025-26 to FY2029-30.
Solid earnings beat with double-digit profit growth, healthy dividend hike of about 31%, and a clean audit opinion are positive signals for shareholders. The 100th AGM is scheduled for June 27, 2025 and the stock may see positive sentiment around the record date of May 30, 2025.